TegMine and Boehringer Ingelheim Collaborate on Cancer Antibody System

TegMine Therapeutics has announced a strategic research and development collaboration with Boehringer Ingelheim to advance its novel 2-Factor Antibody System for cancer treatment, announced in a press release. This partnership aims to develop more selective and better-tolerated antibody-drug conjugates (ADCs) targeting up to three cancer antigens.

The collaboration will leverage TegMine's proprietary platform to discover tumor-specific glycan epitopes, which are largely absent in healthy tissues. The 2-Factor Antibody System requires dual glycan/protein-based recognition, enhancing specificity and efficacy while reducing toxicity. Initially, the program will focus on a clinically validated antigen, with the potential to expand to two additional targets.

Under the agreement, TegMine will receive an upfront payment, research funding per target, and a target option fee for each additional target. The company is also eligible for milestone payments and royalties on net sales for any products developed through this collaboration. Boehringer Ingelheim will hold global development and commercial rights for each target generated.